Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript

Arthur He: Thanks, Mary. My second question is for the 0165. Just curious. So what are the gating [Technical Difficulty] study right now for these programs moving to the clinic next year?

Howard Robin: JZ, you want to cover that?

Jonathan Zalevsky: Sure. Hey Arthur, thanks for the question. We’ve advanced the program, like, as I mentioned earlier, to identifying candidate and then to characterizing it in vitro and in vivo. We’ve also run large animal studies like a non-GLP toxicology study. We’ve also moved into — we’ve made a manufacturing cell line, and we’ve also moved it to the beginnings of manufacture. So the next big milestones for our IND-enabling package, which is no different than any other IND-enabling package is the GLP toxicology, which for us will come at the end of the year. It will start then. And then also advancing into GMP manufacture of the Phase 1 supply. But as I said, we’ve already done a lot of work and a lot of the major work like non-GLP toxicology studies in primates, for example, that give us the confidence and to move through these IND-enabling studies.

Operator: Thank you. And I am showing no further questions from our phone lines. And I’d like to pass the conference back to Howard Robin for any closing remarks.

Howard Robin: Very well, thank you, everyone, for joining us today, and we remain focus on executing on the development of REZPEG and of course, our other immunology programs, like NKTR-0165. I want to thank all of our employees for their extremely diligent and hard work. And the coming years should be an exciting one. And we look forward to providing you with updates on our progress. So thanks for joining us today. Appreciate it.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect. Everyone, have a wonderful day.